Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
59
AXSM Quote, Financials, Valuation and Earnings
Last price:
$148.01
Seasonality move
:
21.92%
Day range:
$142.62 - $148.72
52-week range:
$75.56 - $152.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.96x
P/B ratio:
101.07x
Volume:
616.9K
Avg. volume:
560.5K
1-year change:
47.09%
Market cap:
$7.5B
Revenue:
$385.7M
EPS (TTM):
-$4.67
Analysts' Opinion
-
Consensus RatingAxsome Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $181.31, Axsome Therapeutics, Inc. has an estimated upside of 21.6% from its current price of $147.81.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $148.00 representing 100% downside risk from its current price of $147.81.
Fair Value
-
According to the consensus of 16 analysts, Axsome Therapeutics, Inc. has 21.6% upside to fair value with a price target of $181.31 per share.
AXSM vs. S&P 500
-
Over the past 5 trading days, Axsome Therapeutics, Inc. has underperformed the S&P 500 by -1.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Axsome Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Axsome Therapeutics, Inc. has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Axsome Therapeutics, Inc. reported revenues of $171M.
Earnings Growth
-
Axsome Therapeutics, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Axsome Therapeutics, Inc. reported earnings per share of -$0.94.
Enterprise value:
7.3B
EV / Invested capital:
25.13x
Price / LTM sales:
12.96x
EV / EBIT:
--
EV / Revenue:
13.09x
PEG ratio (5yr expected):
-1.28x
EV / Free cash flow:
-72.44x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$506.9M
Return On Assets:
-37.81%
Net Income Margin (TTM):
-40.9%
Return On Equity:
-327.97%
Return On Invested Capital:
-82.07%
Operating Margin:
-19.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $223.4M | $338.5M | $561.3M | $104.8M | $171M | |
| Gross Profit | $194.2M | $300.8M | $506.9M | $94.3M | $156.7M | |
| Operating Income | -$183.6M | -$245.9M | -$194.8M | -$46.2M | -$32.9M | |
| EBITDA | -$175.3M | -$238.4M | -$186.1M | -$44.2M | -$30.5M | |
| Diluted EPS | -$4.53 | -$6.54 | -$4.67 | -$1.34 | -$0.94 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $115M | $252.4M | $511.8M | $479.1M | $565.3M | |
| Total Assets | $116.6M | $339M | $600.9M | $561.5M | $669.3M | |
| Current Liabilities | $24.7M | $60.3M | $114.7M | $196.2M | $360.3M | |
| Total Liabilities | $73.9M | $181.6M | $331.3M | $468.6M | $595.5M | |
| Total Equity | $42.7M | $157.4M | $269.5M | $92.9M | $73.7M | |
| Total Debt | $50.1M | $93.9M | $185.1M | $190.7M | $147.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$142.3M | -$132.6M | -$101M | -$18.6M | $1M | |
| Cash From Investing | -$755.9K | -$247K | -$439K | -$90K | -$58K | |
| Cash From Financing | $332.1M | $43.6M | $99.3M | $30.4M | $21.3M | |
| Free Cash Flow | -$143M | -$132.8M | -$101.4M | -$18.7M | $988K | |
AXSM
Sector
Market Cap
$7.5B
$28.4M
Price % of 52-Week High
96.65%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-2.09%
-1.32%
1-Year Price Total Return
47.09%
-22.19%
Beta (5-Year)
0.476
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$149.05
200-day SMA
Buy
Level
$117.30
Bollinger Bands (100)
Buy
Level
109.07 - 136.89
Chaikin Money Flow
Buy
Level
66.9M
20-day SMA
Buy
Level
$144.21
Relative Strength Index (RSI14)
Buy
Level
58.77
ADX Line
Sell
Level
28.4
Williams %R
Neutral
Level
-30.2834
50-day SMA
Buy
Level
$133.04
MACD (12, 26)
Buy
Level
4.42
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
216.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.8166)
Sell
CA Score
(Annual)
Level (-3.4824)
Buy
Beneish M-Score
(Annual)
Level (-3.4566)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.7861)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, AXSM has received 16 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AXSM average analyst price target in the past 3 months is $181.31.
-
Where Will Axsome Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Axsome Therapeutics, Inc. share price will rise to $181.31 per share over the next 12 months.
-
What Do Analysts Say About Axsome Therapeutics, Inc.?
Analysts are divided on their view about Axsome Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Axsome Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $148.00.
-
What Is Axsome Therapeutics, Inc.'s Price Target?
The price target for Axsome Therapeutics, Inc. over the next 1-year time period is forecast to be $181.31 according to 16 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AXSM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Axsome Therapeutics, Inc. is a Buy. 16 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AXSM?
You can purchase shares of Axsome Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Axsome Therapeutics, Inc. shares.
-
What Is The Axsome Therapeutics, Inc. Share Price Today?
Axsome Therapeutics, Inc. was last trading at $148.01 per share. This represents the most recent stock quote for Axsome Therapeutics, Inc.. Yesterday, Axsome Therapeutics, Inc. closed at $147.81 per share.
-
How To Buy Axsome Therapeutics, Inc. Stock Online?
In order to purchase Axsome Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AXSM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AXSM
Sector
P/E ratio
--
23.66x
PEG ratio
-1.28x
-0.01x
P/B ratio
101.07x
1.84x
Price / LTM sales
12.96x
1.60x
Growth Metrics
AXSM
Sector
Revenue growth
63.22%
4.85%
Earnings growth
29.64%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.90
-$0.20
Profitability
AXSM
Sector
Profitability FY 2024
$344.4M
$3.6M
Return on invested capital
-82.07%
-30.98%
Return on assets
-37.81%
-27.62%
Return on equity
-327.97%
-36.69%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Feb
17
Estimated Next Earnings Date
Feb
2
Balance Sheet
AXSM
Sector
Total cash
$325.3M
$27.2M
Short term investments
--
$25.7M
Total assets
$568.5M
$79.9M
Long term debt
$147.9M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
